Benefits of Oxytocin in Obstructive Sleep Apnea (OSA) Patients Using Continuous Positive Airway Pressure (CPAP) Machine

• Status: Recruiting
• Trial end date: 2024-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will investigate if an intra-nasal nose spray of the drug oxytocin can decrease the amount of pressure needed from the automatic Continuous Positive Airway Pressure (CPAP) device while sleeping decreasing some of the harmful effects of low oxygen in people with sleep apnea.

This study will last 35 nights and involves spending three nights in the sleep lab at George Washington University. There are no additional costs to participants and no compensation for being involved in the study.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Vivek Jain
• Collaborator: George Washington University
• Treatments: Oxytocin

Criteria

Inclusion Criteria:

• Men or women 18 years of age or older.

Exclusion Criteria:

• subjects not willing to or otherwise unable to use CPAP for treatment of OSA.

• Presence of other sleep disorders

• Pregnant or breastfeeding women

• Women of child-bearing age (WOCBA) not willing or unable to use an accepted method to avoid pregnancy for the entire duration of the study

• Prisoners or subjects who are involuntarily incarcerated

• Subjects who are compulsorily detain or treatment of either a psychiatric or physical (i.e. infectious disease) illness

• Patients unable to give consent because of a language barrier, or other reason.